Methods and kits for assessing clinical outcome of autoimmune disease

摘要

By comparing biomarkers of CD45RA, TNF-alpha, and/or CXCR5 from a CD3 ⁺ CD4 ⁺ T cell population, eg, where the subject ceases to take a biological disease modifying anti-rheumatic drug (DMARD) Methods and kits for assessing the clinical outcome of an autoimmune disease, specifically disease relapse, are disclosed. In a specific embodiment, the ratio of the first subset of CD3 ⁺ CD4 ⁺ CD45RA ⁻ TNFA ⁺ (memory) T cells to the second subset comprising CD3 ⁺ CD4 ⁺ CD45RA ⁺ TNFA ⁺ (untreated) T cells is determined. However, an increase in this ratio is indicative of juvenile idiopathic arthritis (JIA) disease flare-up status. In another embodiment, enrichment of the CD45RA ^- CR5 ⁺ subset among T cell populations indicates a possible flare-up in JIA due to enhanced memory retention through B cell interactions. In another embodiment, additional markers including IL-6, CCR6, CD152, and PD1 are also determined. [Selection diagram] Fig. 3